Mechanistic and preclinical studies showed Hafnia alvei is able to produce Caseinolytic peptidase B, a protein mimicking the hormone of satiety alpha-MSH
French microbiome biotech TargEDys has announced the publication of a study of 230 overweight adults supplemented for 12 weeks, reportedly demonstrating the efficacy of the company’s Hafnia alvei HA4597 probiotic for improving weight loss, hip circumference reduction and metabolic parameters. The company says this is related to the action of the probiotic and its postbiotic ClpB on feeling of fullness.
Mechanistic and preclinical studies showed Hafnia alvei is able to produce Caseinolytic peptidase B, a protein mimicking the hormone of satiety alpha-MSH, and to reduce food intake in murine models of obesity. The company says the results confirm the efficacy of this PreciBiomic strain in supporting feeling of fullness and weight loss in overweight subjects, as well as reducing hip circumference and glycemia.
Participants in the probiotic experienced an average of 3.6% weight loss in 12 weeks. The company says this reflects a shift in approach to more precision probiotics, with enhanced efficacy owing to a precise understanding of the molecular mechanism of action.
Hafnia alvei can be found in the products EnteroSatys and Satylia in France, Portugal, Italy and Slovenia, and TargEDys is looking for distribution partners to make this breakthrough solution for the prevention of obesity available to consumers worldwide.
Grégory Lambert, CEO of TargEDys, said: “This will be a game-changer in the sector of weight management, with finally a solution that meets consumers expectations in terms of safety and naturality, while also bringing a real, demonstrated efficacy based on molecular mimicry and the biochemical regulation of appetite.”